In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Amneal and Impax Labs merge to create leading generics company

Executive Summary

Amneal Pharmaceuticals LLC and Impax Laboratories Inc. entered into a merger agreement in which the two companies will combine in an all stock transaction valued at approximately $6.2bn in market value (assumes per share price of $19.95) or $8.7bn in enterprise value (including net debt of $2.5bn; 4.8x and 13.9x EV to 2017 combined pro forma revenue and EBITDA, respectively).
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Topical Delivery
      • Transdermal
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies